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Clinical trials of disease stages in COVID 19: complicated and 
often misinterpreted
As of July 28, 2020, 1840 clinical trials were registered 
globally, with 1001 clinical trials recruiting patients 
for COVID-19 management.1 Despite this large 
number, only 30 trials have been published as peer-
reviewed or preprint publications.2 Media reports and 
prepublications on medRxiv and bioRxiv represent the 
most frequent mechanism for data sharing, with wide 
public reach and usually with little detail. However, 
with inadequate details on the trials and only superficial 
scrutiny by the public and scientific decision makers, 
the consequences have had disastrous effects on other 
clinical trial funding, permissions, recruitment, and 
interpretation.
Broadly, COVID-19 clinical trials target at least five 
stages of the disease process (appendix): pre-exposure 
prophylaxis, post-exposure prophylaxis, outpatient 
treatment, hospital admission, and late-stage critical 
care (admission to an intensive care unit). More 
clinical stages for COVID-19 arguably exist if looking 
at subgroup manifestations of COVID-19. Despite the 
overwhelmingly large number of trials being done for 
COVID-19, it is important to note that the majority of 
these trials (1134 [61·6%] of 1840) involve patients who 
have been admitted to hospital.
Among all clinical trials, those receiving the 
greatest media and scientific attention include the 
WHO SOLIDARITY trial (ISRCTN83971151) and 
the Randomised Evaluation of Covid Therapy trial 
(RECOVERY; ISRCTN50189673). Both of these 
randomised trials target patients receiving treatment 
in hospital and have proven the ineffectiveness of 
lopinavir–ritonavir3 and hydroxychloroquine4 for 
patients admitted to hospital with COVID-19. Although 
both trials provide convincing evidence for patients 
requiring hospital admission, these findings cannot 
be translated to other disease states. For example, 
in the RECOVERY trial, the clinical efficacy of low-
dose dexamethasone is demonstrated only among 
patients receiving invasive mechanical ventilation or 
oxygen.5 Clinical trials investigating treatment options 
in other disease states are experiencing unintended 
consequences of early dissemination of this inpatient 
evidence. Many trials evaluating chloroquine-based 
treatments and protease inhibitors for pre-exposure 
prophylaxis and outpatient treatment have had 
funding and ethics approvals rescinded based on media 
attention on findings from hospital settings. This 
misinterpretation of disease states exists among both 
the public and the scientific communities.
Different COVID-19 disease stages encompass different 
biological responses, and pharmaceutical interventions 
might exhibit different effects according to concurrent 
pathogenesis. The initial remdesivir randomised trial 
on patients receiving treatment in hospital, in which 
the median time to remdesivir initiation after symptom 
onset was 11 days, did not show important statistical 
benefits for time to clinical improvement.6 A subsequent 
randomised trial that initiated remdesivir at a median of 
9 days after symptom onset, by contrast, found a shorter 
recovery time in patients with less severe pulmonary 
disease than in the placebo group.7 The findings support 
the likely efficacy of this antiviral early in disease 
when viral replication predominates. Conversely, the 
dexamethasone findings in the RECOVERY trial found 
benefit in patients with more severe disease requiring 
oxygen or respiratory support,5 supporting an anti-
inflammatory effect when inflammation pathology 
predominates. As seen for other viral infections such as 
influenza and varicella zoster, there is a need for early 
antiviral treatment for COVID-19 because antivirals 
are probably most effective when administered early 
in an infection, whereas systemic hyperinflammation 
rather than viral pathogenicity dominates later stages of 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection.8 Differentiation of effects based on 
an antiviral’s mechanism of action is also anticipated 
with SARS-CoV-2, with interventions affecting viral 
attachment being more dependent on early initiation 
than therapeutics targeting other parts of the viral cell 
cycle.9
Although it is clear that some therapies have no 
clinical benefits in patients admitted to hospital, there 
is much uncertainty, and thus clinical equipoise, to 
justify continuing clinical trials in other COVID-19 
disease states. Most ongoing trials are focusing on 
participants admitted to hospital, and generalising 
See Online for appendix
Published Online 




e1250 www.thelancet.com/lancetgh   Vol 8   October 2020
their findings to ambulatory patients might potentially 
harm opportunities to identify effective outpatient 
treatments. Arguably, the largest impact on COVID-19 
can be achieved by identifying effective early treatments 
to prevent hospital admission. Although we hope that 
scientific funders and ethics review boards will recognise 
the nuances of COVID-19 disease states, this has not 
been uniformly the case so far. Delaying or rescinding 
funding or approvals for clinical trials based on findings 
from clinically different populations might importantly 
reduce our likelihood of finding effective therapies 
across the spectrum of clinical disease states.
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